Therefore, a combination treatment, including HDAC or DNA methylation inhibitors and retinoic acid drugs, would be a promising strategy in treating high-risk neuroblastoma (Rettig et al., 2015; Westerlund et al., 2017). The gene discussed is HDAC9; the disease is neuroblastoma.